NCT06326411 - A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Biotech Hunter

Enrollment

230

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2029

Conditions

OncologyMEK MutationRAF Gene MutationRas (KRAS or NRAS) Gene MutationMelanomaNSCLCGliomaSolid Tumor, AdultMAPK Pathway Gene Mutation

Interventions

DRUG

NST-628

NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.

Trial Locations (23)

120

RECRUITING

Gallipoli Medical Research Centre- Greenslopes Private Hospital, Greenslopes

2010

RECRUITING

The Kinghorn Cancer Center, St. Vincent's Health Network, Darlinghurst

2031

RECRUITING

Scientia Clinical Research, Ltd, Randwick

3144

RECRUITING

Cabrini Health Limited, Malvern

RECRUITING

Cabrini Hospital, Malvern

5042

RECRUITING

Southern Oncology Research Unit, Adelaide

10016

RECRUITING

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

10032

RECRUITING

Columbia University Medical Center, New York

10065

RECRUITING

Memorial Slone Kettering Cancer Center, New York

14263

RECRUITING

Roswell Park, Buffalo

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

22031

RECRUITING

NEXT Oncology - Virginia, Fairfax

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

SCRI Oncology Partners, Nashville

37232

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

75039

RECRUITING

NEXT Oncology - Dallas, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

78758

RECRUITING

NEXT Oncology - Austin, Austin

80218

RECRUITING

Sarah Cannon Research Institute at Health ONE, Denver

84119

RECRUITING

START Moutain Region, West Valley City

90024

RECRUITING

UCLA Hematology/Oncology, Westwood, Los Angeles

94158

RECRUITING

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

06511

RECRUITING

Yale Cancer Center, New Haven